|
|
Blood, Vol. 112, Issue 13, 4924-4934, December 15, 2008
Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping
Blood Johnson et al.
112: 4924
Supplemental materials for: Johnson et al
Files in this Data Supplement:
- Table S1. Thromboembolic summary of Myeloma IX samples (PDF, 13.2 KB)
- Table S2 (PDF, 41.5 KB) -
Part 1: SNPs associated to a permutated p <0.05 with thalidomide VTE tested by Fisher’s allelic test - Myeloma IX. Part 2: SNPs associated to a permutated p <0.05 with thalidomide VTE with tested by Fisher’s allelic test - Myeloma IX.
- Table S3 (PDF, 23.6 KB) -
Part 1: SNPs associated to a permutated p <0.05 with thalidomide VTE, showing the most significant genetic model - Myeloma IX. Part 2: SNPs associated to a permutated p <0.05 with thalidomide VTE, showing the most significant genetic model - Myeloma IX.
- Table S4. SNPs associated to a permutated p <0.05 with non-thalidomide VTE tested by Fisher’s allelic test - Myeloma IX (PDF, 17.8 KB)
- Table S5 (PDF, 34.9 KB) -
Part 1: SNPs associated to a permutated p <0.05 with non-thalidomide VTE, showing the most significant model - Myeloma IX. Part 2: SNPs associated to a permutated p <0.05 with non-thalidomide VTE, showing the most significant model - Myeloma IX.
- Table S6 (PDF, 18.5 KB) -
Part 1: SNPs associated to a permutated p < 0.05 with thalidomide VTE, tested by Fisher’s allelic test - Hovon-50 and ECOG EA100. Part 2: SNPs associated to a permutated p < 0.05 with thalidomide VTE, tested by Fisher’s allelic test - Hovon-50 and ECOG EA100.
|
|
